Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

July 10, 2017

Conditions
Cystinosis
Interventions
DRUG

RP103

DRUG

Cystagon®

Trial Locations (14)

30322

Emory Children's Center, Atlanta

60614

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine / Texas Childrens Hospital, Houston

94115

California Pacific Medical Center (CPMC) Research Institute, San Francisco

94305

Stanford University Medical School, Stanford

Unknown

University Hospital of Leuven, Leuven

Hospices Civils de Lyon, Lyon

Hôpital Necker-Enfants Malades, Paris

Hôpital Robert Debré, Paris

Ospedale Pediatrico Bambino Gesù, Rome

Radboud University Nijmegen Medical Center, Nijmegen

Queen Elizabeth Hospital Birmingham, Birmingham

Great Ormond Street, London

Guy's Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01733316 - Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis | Biotech Hunter | Biotech Hunter